Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2912804 | 0.77 | LMNA (0.40) | LMNAALDH1A1SMN1; SMN2KDM4EDUSP3 | |
| SCHEMBL15887085 | 0.75 | — | — | |
| SCHEMBL2912805 | 0.75 | — | — | |
| SCHEMBL27786380 | 0.73 | LMNA (0.36) | LMNAALDH1A1SMN1; SMN2KDM4EDUSP3 | |
| SCHEMBL27786849 | 0.73 | LMNA (0.36) | LMNAALDH1A1SMN1; SMN2KDM4EDUSP3 | |
| SCHEMBL27505436 | 0.73 | LMNA (0.36) | LMNAALDH1A1SMN1; SMN2KDM4EDUSP3 | |
| SCHEMBL27832027 | 0.73 | LMNA (0.36) | LMNAALDH1A1SMN1; SMN2KDM4EDUSP3 | |
| SCHEMBL27815197 | 0.73 | LMNA (0.36) | LMNAALDH1A1SMN1; SMN2KDM4EDUSP3 | |
| SCHEMBL141573 | 0.72 | — | — | |
| Water SCHEMBL27952503 | 0.71 | LMNA (0.35) | LMNAALDH1A1KDM4EDUSP3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6511677-B1 | Oral drug delivery system; such as octadeca-2,4-dienoyl-polyethylene glycol-succinic acid with covalently bound ligand that targets intestine mucosal tissue | ORASOMOL TECHNOLOGIES, INC. | 2003-01-28 | — | — | US | disclosed |
| US-6500453-B2 | DRUG DELIVERY | ORASOMOL TECHNOLOGIES, INC. | 2002-12-31 | — | — | US | disclosed |
| US-20020041861-A1 | Novel polymerizable fatty acids, phospholipids and polymerized liposomes therefrom | ORASOMAL TECHNOLOGIES, INC. | 2002-04-11 | — | — | US | disclosed |
| US-6187335-B1 | DRUGS, POLYESTERETHER COPOLYMERS AND PHOSPHOLIPIDS | ORASOMAL TECHNOLOGIES, INC. | 2001-02-13 | — | — | US | disclosed |
| WO-2000076476-A1 | ADJUVANT-CONTAINING POLYMERIZED LIPOSOMES FOR ORAL, MUCOSAL OR INTRANASAL VACCINATION | ENDOREX CORPORATION (US) | 2000-12-21 | — | — | WO | disclosed |
| EP-1049759-A1 | NOVEL POLYMERIZABLE FATTY ACIDS, PHOSPHOLIPIDS AND POLYMERIZED LIPOSOMES THEREFROM | Orasomal Technologies, Inc. (US) | 2000-11-08 | — | — | EP | disclosed |
| WO-1999033940-A1 | NOVEL POLYMERIZABLE FATTY ACIDS, PHOSPHOLIPIDS AND POLYMERIZED LIPOSOMES THEREFROM | ORASOMAL TECHNOLOGIES, INC. (US) | 1999-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020041861-A1 | Novel polymerizable fatty acids, phospholipids and polymerized liposomes therefrom | SGMS1, SGMS2, PHOSPHO1 | LMNA 2418/4885ALDH1A1 4723/4885SMN1; SMN2 4501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.